JAKs, Flares & Rescue Plans: The Art of the Atopic Dermatitis Dose-Down 🎙️

In this rapid-fire post-AAD recap, dermatologist Faculty Dr. Julien Ringuet joins the Skin and Joints Podcast to tackle a question that comes up all the time in real-world atopic dermatitis care: once a patient is doing well, can we safely step down therapy without sending their skin into rebellion?

Using newly presented data on abrocitinib dose down-titration from the JADE program, Dr. Ringuet walks through what happens when patients who respond to 200 mg transition to 100 mg for long-term maintenance—and what clinicians should do if disease control starts to slip. Spoiler: stepping down is not a cliff dive.

Along the way, we cover the “so what?” behind the numbers: who may be a good candidate for dose reduction, how to define loss of control beyond just visible skin lesions, why itch and sleep still deserve centre stage, and how shared decision-making can turn a dosing conversation into a true treatment partnership.

This episode is for clinicians who want to move beyond poster reading and into practical, exam-room-ready conversations about JAK inhibitors, maintenance dosing, treat-to-target thinking, flare management, and individualized care in atopic dermatitis.

Learning Objectives 📚

After listening to this episode, listeners should be able to:

1. Describe the clinical rationale for considering abrocitinib dose down-titration in selected patients with atopic dermatitis.
2. Interpret key long-term efficacy and flare data from the JADE Regimen/JADE Extend analyses in the context of real-world maintenance therapy.
3. Identify patient factors that may support or discourage dose reduction, including depth of response, flare history, adherence, follow-up reliability, quality-of-life burden, and patient preferences.
4. Explain how to counsel patients that step-down therapy is an option—not a guarantee—and that itch, sleep disruption, visible flare, and increased topical use can all signal loss of control.
5. Apply a treat-to-target mindset using both clinician-reported outcomes, such as EASI, IGA, and BSA, and patient-reported outcomes, including itch, sleep, satisfaction, and quality of life.
6. Recognize key caveats when applying clinical trial data to real-world practice, including responder-enriched populations, rescue therapy design, and as-observed analyses.

#SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

ABOUT Dr. Julien Ringuet

Dermatologist, Quebec City, QC

Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).
He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).
Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

Supported by an IME Grant from PFIZER.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca